S-1/A: HCW Biologics Plans $5M Unit Offering Amid Nasdaq Compliance Push

HCW Biologics Inc. is offering up to 7.69 million units, each comprising common stock or pre-funded warrants and common stock warrants, aiming to raise $5 million to fund clinical development and address Nasdaq listing compliance.

Summary

• HCW Biologics Inc. is offering up to 7,691,124 units, each consisting of one share of common stock (or one pre-funded warrant) and one common stock warrant, at an assumed public offering price of $0.6501 per unit, targeting gross proceeds of approximately $5,000,000.
• The estimated net proceeds from this offering are approximately $4.2 million, which will be allocated to preclinical and clinical development (including HCW9302 trials), research and development for TRBC molecules, business development, patent portfolio expansion, and general corporate purposes.
• The company is a clinical-stage biopharmaceutical firm focused on developing immunotherapies for diseases driven by chronic inflammation, including age-related conditions and cancer, utilizing its TOBI and TRBC platform technologies.
• HCW9302, a lead product candidate, has initiated a Company-sponsored Phase 1 clinical trial for patients with alopecia areata, an autoimmune disorder.
• The company recently entered into an Amended and Restated License, Research and Co-Development Agreement with Beijing Trimmune Biotech Co., Ltd. (Trimmune) for HCW11-006, which includes a $3.5 million upfront cash license fee (half received on February 13, 2026, the remainder due by March 6, 2026) and a minority co-founder equity position in Trimmune valued at approximately $3.5 million.
• HCW Biologics regained compliance with Nasdaq's Equity Rule as of December 31, 2025, but remains under a Mandatory Panel Monitor for one year through February 16, 2027.
• The company settled approximately $7.4 million in outstanding legal fees on December 30, 2025, through $2.0 million in cash payments ($500,000 paid, $1.5 million contingent on Trimmune payment) and a contingent promissory note.
• As of September 30, 2025, the company had cash and cash equivalents of $1.1 million and reported cumulative net losses of $106.5 million since inception, raising substantial doubt about its ability to continue as a going concern.
• A 1-for-40 reverse stock split was effective on April 11, 2025, and all share numbers and per-share amounts in the prospectus reflect this adjustment retrospectively.
• A warrant inducement agreement on November 19, 2025, with Armistice Capital Master Fund Ltd. resulted in the exercise of 1,510,205 existing warrants for approximately $4.0 million in gross proceeds and the issuance of new unregistered warrants to purchase 3,020,410 shares at $2.41 per share.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a high-risk offering given the company's substantial going concern doubt, significant accumulated losses, and reliance on future capital raises. While there are positive clinical and licensing developments, the financial instability and dilution risks are considerable.

Positives

• Secured an Amended and Restated License, Research and Co-Development Agreement with Trimmune for HCW11-006, including a $3.5 million upfront cash payment (half received) and a $3.5 million equity stake in Trimmune.
• Initiated a Company-sponsored Phase 1 clinical trial for the lead product candidate, HCW9302, in patients with alopecia areata, marking progress in clinical development.
• Regained compliance with Nasdaq's Listing Rule 5550(b)(1) (the Equity Rule) as of December 31, 2025, addressing a significant listing concern.
• Successfully settled approximately $7.4 million of outstanding legal fees for $2.0 million in cash payments and a contingent promissory note, reducing a substantial liability.
• Completed a warrant inducement transaction with Armistice Capital Master Fund Ltd., generating approximately $4.0 million in gross proceeds.

Negatives

• There is substantial doubt regarding the company's ability to continue as a going concern, with only $1.1 million in cash and cash equivalents as of September 30, 2025.
• The company has incurred significant operating losses since its inception, with cumulative net losses reaching $106.5 million as of September 30, 2025.
• No products have been approved for commercial sale, and the company currently generates no revenue from product sales.
• The current offering is a 'reasonable best efforts' offering with no minimum amount of securities required to be sold, meaning the actual proceeds may be substantially less than the maximum target.
• New investors in this offering will experience immediate and substantial dilution of $0.16 per share based on the assumed public offering price.
• Outstanding obligations in accounts payable totaled $19.4 million as of September 30, 2025, including $2.7 million for construction of a manufacturing facility.
• The company is involved in legal proceedings related to the manufacturing facility construction, including a complaint from its general contractor (BE&K Building Group) and a subcontractor (Fisk Electric Company).
• The Wugen License, a source of past revenue, was voluntarily suspended for one year beginning May 29, 2025.
• Common Stock Warrants offered in this transaction are not exercisable without Shareholder Approval, and if not obtained, they will have no value.

Risks

• The issuance and sale of shares of Common Stock may cause substantial dilution and the price of our Common Stock to decline.
• The potential issuance and sale of shares of Common Stock under the Equity Purchase Agreement and other warrants may cause substantial dilution and the price of our Common Stock to decline.
• Our need for future financing may result in the issuance of additional securities, which will cause investors to experience dilution.
• We have incurred significant financial losses since our inception and expect to incur losses for the foreseeable future; we have no products approved for commercial sale and may never achieve or maintain profitability.
• There is substantial doubt regarding our ability to continue as a going concern based on our cash and cash equivalents as of September 30, 2025; we will need to raise additional funding, which may not be available on acceptable terms, if at all.
• Failure to obtain capital when needed may force us to delay, limit or terminate our product development efforts or other operations.
• If we fail to maintain an effective system of disclosure controls and internal control over financial reporting, our ability to produce timely and accurate financial statements could be impaired.
• Remaining outstanding legal fee obligations could have a negative material impact on our business and operations.
• We are subject to a Mandatory Panel Monitor by Nasdaq for one year from January 7, 2026, and if found out of compliance again, we will face a Delist Determination Letter.
• Our clinical trials may fail to demonstrate the safety and efficacy of our product candidates, which would prevent, delay or limit regulatory approval and commercialization.
• Preliminary, topline or interim data from our clinical trials may change as more patient data becomes available and are subject to audit and verification procedures.
• The development and commercialization of biopharmaceutical products is subject to extensive, lengthy, time-consuming, and inherently unpredictable regulatory approval processes.
• Clinical drug development is a lengthy and expensive process with uncertain timelines and outcomes; prolonged or delayed trials could prevent or delay commercialization.
• Even if our product candidates obtain regulatory approval, we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense, labeling restrictions, or market withdrawal.
• We expect to rely on patents and other intellectual property rights to protect our technology, the prosecution, enforcement, defense, and maintenance of which may be challenging, time-consuming and costly.
• We rely on third parties to manufacture our product candidates; any failure could delay or impair our ability to initiate or complete clinical trials, obtain regulatory approvals or commercialize approved products.
• Our information technology systems, or those used by our third-party contractors or consultants, may fail or suffer security breaches, which could adversely affect our business.
• We operate in highly competitive and rapidly changing industries, which may result in others discovering, developing or commercializing competing products before or more successfully than we do.
• Failure to successfully identify, develop, and commercialize additional product candidates could impair our ability to grow.
• Even if approved, our products may not gain market acceptance, which would materially adversely affect our business, financial condition, and results of operations.
• We currently have no marketing, sales, or distribution infrastructure and intend to either establish one or outsource this function, both carrying substantial risks.
• We may not realize the benefits of any existing or future co-development or out-licensing arrangement, and if we fail to enter into new strategic relationships, our business could be materially adversely affected.
• We are exposed to costly and damaging product liability claims, and our product liability insurance may not cover all damages.
• FDA-regulated industries face substantial uncertainty regarding new Administration's initiatives, which could prevent, limit or delay development and regulatory approval.
• We face potential liability related to the privacy of health information we obtain from clinical trials, research institutions, and individuals.
• Our Common Stock price may be volatile or may decline regardless of our operating performance, resulting in substantial losses for investors.
• Our principal stockholders and management own a significant percentage of our stock and may be able to exert control over matters subject to stockholder approval.
• Potential future sales pursuant to registration rights and under Rule 144 may depress the market price for our shares of Common Stock.
• FINRA has adopted sales practice requirements that may limit a stockholder's ability to buy and sell our Common Stock.
• Volatility in the company's share price could subject the company to securities class action litigation.
• A short squeeze due to a sudden increase in demand for shares of our Common Stock that largely exceeds supply and/or focused investor trading in anticipation of a potential short squeeze have led to, may be currently leading to, and could again lead to, extreme price volatility in shares of our Common Stock.
• Increases in market interest rates may cause potential investors to seek higher returns and therefore reduce demand for our Common Stock, which could result in a decline in our stock price.
• If securities or industry analysts do not publish research or reports about the Company, or publish negative reports, the Company's share price and trading volume could decline.
• Because the Company does not anticipate paying any cash dividends in the foreseeable future, capital appreciation, if any, would be your sole source of gain.
• Future offerings of debt and/or preferred equity securities could adversely affect the market price of our Common Stock.
• Anti-takeover provisions contained in our charter and bylaws, as well as provisions of Delaware law, could impair a takeover attempt.
• Our charter and bylaws provide that the Court of Chancery of the State of Delaware and the federal district courts of the United States of America will be the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders' ability to obtain a favorable judicial forum.

Future Outlook

The company intends to use the proceeds from this offering to fund the continued progress of its preclinical and clinical development, including clinical trials for HCW9302, research and development costs for TRBC molecules, expansion of business development programs, identification of compounds for out-licensing, and expansion of its patent portfolio. The strategic focus remains on developing protein-based immunotherapies for diseases promoted by chronic inflammation, particularly age-related conditions and cancer, with an emphasis on subcutaneous injection and targeting diseases without curative FDA-approved treatments.

Management Comments

• "Our immunotherapeutics represent a new class of drug that we believe has the potential to fundamentally change the treatment of cancer and many other diseases and conditions that are promoted by chronic inflammation – and in doing so, improve patients quality of life and possibly extend longevity."
• "Our focus continues to be to develop protein-based immunotherapies that are administered by subcutaneous injection. We remain focused on diseases promoted by chronic inflammation driven by senescence, including cancer, especially age-related diseases. The diseases we will target will have no curative FDA approved treatments. Finally, we have selected programs that include life-threatening diseases, such as pancreatic and ovarian cancer, as well as quality-of-life indications, such as alopecia areata and senile lentigo."

Industry Context

StockSavvy.ai notes that HCW Biologics operates in the highly competitive and rapidly evolving biopharmaceutical industry, specifically targeting chronic inflammation and age-related diseases with novel immunotherapies. The focus on subcutaneous injection for protein-based immunotherapies aligns with industry trends seeking less invasive and more patient-friendly drug delivery methods. The company's strategy of out-licensing non-core assets is a common approach for clinical-stage biotechs to generate non-dilutive capital and focus internal resources on lead candidates, similar to how larger pharmaceutical companies manage extensive pipelines. The recent FDA approval of Anktiva (ALT-803), an IL-15 agonist receptor discovered by HCW's CEO, Hing C. Wong, highlights the potential of their platform technology and management's expertise in developing blockbuster immunotherapeutics, providing a strong historical precedent for their current endeavors.

Comparison to Industry Standards

• HCW Biologics' lead product candidate, HCW9302, is a first-in-kind interleukin-2 (IL-2) fusion molecule. This positions it in a competitive landscape with other IL-2 therapies, such as those developed by Nektar Therapeutics (Bempegaldesleukin, NKTR-214, which faced clinical setbacks) and Sanofi (SAR444245, an IL-2 mutein). HCW9302's focus on regulatory T (Treg) cells for autoimmune diseases like alopecia areata differentiates it from traditional IL-2 approaches primarily targeting effector T cells in oncology.
• The company's TRBC platform for multi-specific cytokines and immune checkpoint inhibitors is comparable to next-generation immunotherapy platforms from companies like Amgen (BiTE antibodies) and Roche (bispecific antibodies), which aim for enhanced specificity and reduced off-target effects.
• The $1.0 billion acquisition of Anktiva (ALT-803) by ImmunityBio in 2017, followed by its FDA approval in 2024 for bladder cancer, sets a high benchmark for HCW Biologics' internal development and out-licensing potential, demonstrating the significant value that can be generated from successful immunotherapy platforms.
• The 'reasonable best efforts' offering with no minimum proceeds is a less favorable financing structure compared to firm commitment underwritings, often seen in smaller or more speculative biotech offerings, indicating higher risk for investors.

Corporate Governance

Legal Proceedings

• Settlement Agreement with Altor BioScience, LLC, NantCell, Inc., and ImmunityBio, Inc. on July 13, 2024, eliminated uncertainty regarding previously disclosed arbitration proceedings.
• Settlement agreement executed on December 30, 2025, for approximately $7.4 million of outstanding legal fees, involving $2.0 million in cash payments and a contingent promissory note.
• Received a summons and complaint from BE&K Building Group on April 17, 2025, regarding unpaid invoices for the construction of a manufacturing facility.
• Received a summons and complaint from Fisk Electric Company on April 28, 2025, a subcontractor involved in the BE&K complaint.
• B&I Contractors, Inc. filed a motion for summary judgment on August 8, 2025, scheduled to be heard on February 19, 2026.
• An ongoing matter involves a claim from a former employer against the founder and CEO, Dr. Wong, for which the company agreed to advance certain defense costs.

Related Party Transactions

• Private Placement (February 20, 2024): Officers and directors purchased 44,643 shares of Common Stock for an aggregate of $2.5 million. Participants included Rebecca Byam ($1,064,999.60), Dr. Hing C. Wong ($1,035,003.20), and Scott Garrett ($200,001.20).
• Secured Note Financing (as of October 31, 2024): Officers and directors purchased $2.9 million of senior secured notes. Participants included Dr. Hing C. Wong ($2,405,000), Rebecca Byam ($220,000), Scott T. Garrett ($140,000), Gary M. Winer ($60,000), Lee Flowers ($25,000), and Rick S. Greene ($25,000).
• Convertible Bridge Notes (May 7, 2025): Officers and directors invested $170,000 in unsecured convertible promissory notes. Participants included Hing C. Wong ($60,000), Scott T. Garrett ($100,000), and Gary M. Winer ($10,000).
• Stock Option Grants: Executive officers received stock option grants as detailed in the Executive Compensation section.
• Indemnification Agreements: The company has entered into indemnification agreements with each of its directors and officers.

Stakeholder Impact

• Shareholders: Will experience immediate and substantial dilution from the current offering. Existing shareholders face potential further dilution from future capital raises and warrant exercises. The 'going concern' doubt and Nasdaq monitoring pose significant risks to investment value.
• Employees: Continued employment and potential equity awards are tied to the company's financial stability and success in product development.
• Customers/Patients: Potential for new immunotherapeutic treatments for various diseases if product candidates successfully complete clinical trials and gain regulatory approval.
• Suppliers/Creditors: Outstanding obligations and legal proceedings related to construction indicate potential payment delays and financial strain on creditors.
• Placement Agent: Maxim Group LLC will receive a 7.0% cash transaction fee of gross proceeds and reimbursement of expenses up to $65,000 from the offering.

Next Steps

• Obtain Shareholder Approval for the exercise of Common Stock Warrants, as required by Nasdaq rules.
• Hold a special meeting of shareholders on or prior to 60 days after the Closing Date to seek Shareholder Approval for the Common Warrants, and if not obtained, call subsequent meetings every 60 days.
• Receive the remaining $1.75 million of the Trimmune upfront cash license fee by March 6, 2026.
• Continue preclinical and clinical development, including advancing the clinical trials for HCW9302.
• Conduct further research and development for TRBC molecules, specifically second-generation T-Cell Engagers and immune checkpoint inhibitors.
• Prepare for business development transactions, including identifying appropriate compounds for out-licensing.
• Expand the patent portfolio for HCW9302 and other new TRBC-based compounds.
• Conduct studies required for pivotal scientific publications.
• Address ongoing legal proceedings related to the manufacturing facility construction.
• Maintain compliance with all Nasdaq listing rules, particularly during the Mandatory Panel Monitor period until February 16, 2027.

Key Dates

Recommendation

The company faces severe liquidity issues, evidenced by the 'substantial doubt about its ability to continue as a going concern' and only $1.1 million in cash as of September 30, 2025, against $19.4 million in past-due obligations. While the current offering aims to raise $5 million, it's a 'reasonable best efforts' offering with no guarantee of success, and even if fully subscribed, it provides only a temporary reprieve. The significant dilution for new investors, coupled with ongoing legal challenges and the inherent high risk of clinical-stage biopharmaceutical development, makes this a highly speculative and unfavorable investment at this time. The Nasdaq Panel Monitor further underscores the precarious financial and operational position.

Keywords

Biopharmaceutical, Immunotherapy, Clinical-stage, Chronic Inflammation, Age-related diseases, Senescence, Cancer, Autoimmune disorders, HCW9302, TRBC platform, Nasdaq, SEC filing, Public offering, Warrants, Pre-funded warrants, Dilution, Going concern, Capital raise, Intellectual property, Clinical trials, Regulatory approval